Lexaria Bioscience (NASDAQ:LEXX) Stock Price Up 13.2%

Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Rating) shares rose 13.2% on Tuesday . The stock traded as high as $0.88 and last traded at $0.78. Approximately 1,658,700 shares changed hands during trading, an increase of 1,683% from the average daily volume of 93,028 shares. The stock had previously closed at $0.69.

Lexaria Bioscience Trading Up 13.2 %

The company has a market capitalization of $4.68 million, a P/E ratio of -0.67 and a beta of 0.59. The firm’s 50 day moving average price is $1.94 and its two-hundred day moving average price is $2.46.

Institutional Investors Weigh In On Lexaria Bioscience

Several large investors have recently made changes to their positions in LEXX. Renaissance Technologies LLC acquired a new stake in shares of Lexaria Bioscience in the 2nd quarter valued at approximately $34,000. Dimensional Fund Advisors LP acquired a new stake in shares of Lexaria Bioscience in the 3rd quarter valued at approximately $37,000. Virtu Financial LLC acquired a new stake in shares of Lexaria Bioscience in the 1st quarter valued at approximately $40,000. Centiva Capital LP acquired a new stake in shares of Lexaria Bioscience in the 2nd quarter valued at approximately $42,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Lexaria Bioscience by 64.8% in the 4th quarter. Susquehanna International Group LLP now owns 66,131 shares of the company’s stock valued at $162,000 after buying an additional 26,012 shares during the last quarter. Institutional investors and hedge funds own 11.56% of the company’s stock.

Lexaria Bioscience Company Profile

(Get Rating)

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS.